Is HER2 amplification predictable by digital immunohistochemistry? - Wikidata - wikimedia - TriplyDB

Is HER2 amplification predictable by digital immunohistochemistry?

Is HER2 amplification predictable by digital immunohistochemistry?

http://www.wikidata.org/entity/Q50288154

about

Primary angiosarcoma of the breast: a case report.Vulvar "proximal-type" epithelioid sarcoma: report of a case and review of the literature.Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy.

P2860

Q36835087-F32D764B-3CA7-4704-87AF-711346A7B520 Q37114845-414F7CAC-C1EA-400A-922D-F700F1BF1D34 Q40264759-1890606C-3F11-4ABE-9015-7AE0FBDD9A88

P2860

Is HER2 amplification predictable by digital immunohistochemistry?

http://www.wikidata.org/entity/Q50288154

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Is HER2 amplification predictable by digital immunohistochemistry?

@en

Is HER2 amplification predictable by digital immunohistochemistry?

@nl

type

label

Is HER2 amplification predictable by digital immunohistochemistry?

@en

Is HER2 amplification predictable by digital immunohistochemistry?

@nl

prefLabel

Is HER2 amplification predictable by digital immunohistochemistry?

@en

Is HER2 amplification predictable by digital immunohistochemistry?

@nl

P1433

Q50288154-F0974ECF-BD69-4051-8E42-2B889D67EF83

P1476

Q50288154-CD6F1EEE-84E5-468D-86F3-AE0B38EED63A

P2093

Q50288154-4DA24A6F-F9A1-4096-B202-12D17072CB78

Q50288154-55271FDD-5A56-480E-85B3-09C9CC58C32E

Q50288154-9369F6FD-50D2-4A87-B6BB-F51250721DA2

Q50288154-BF16E143-789B-4EC4-8A4D-6F5865033C7E

Q50288154-E85A209F-DE9B-4AE4-98E1-462CE79003E4

Q50288154-E9B6CB97-02C2-4E3B-8FC8-303DF82EDD72

P2860

Q50288154-0E392F8A-AC59-45E2-9D4C-3DCFB6A2C34F

Q50288154-13286F4C-9B3A-4798-915E-A0C7526525CF

Q50288154-525F98A4-5D84-4CF4-8890-05D8B65E239C

Q50288154-6A8D5A40-433A-4A14-A538-A474983F52B0

Q50288154-6D6BB947-9211-425E-ADC7-5C3230C9E499

Q50288154-A293A21E-96AE-4138-878D-B3B65900CED1

Q50288154-BE459E66-485D-4D40-B75B-A33F4DC940EB

Q50288154-F504777B-7C1F-4A80-BE33-ED3CD64FC2E0

P2888

Q50288154-50CCBB2A-6345-4900-8494-A9A0398FE7B4

P304

Q50288154-2881C09E-174B-4ED3-8013-E1896DC9A1DE

P31

Q50288154-5C4537AD-0586-495B-8921-D9D79A29A4C9

P356

Q50288154-3D37DEA8-EBBF-4B4C-9699-2EA05D651CF8

P433

Q50288154-57157D26-F70C-446F-8B95-96807F8E9E7F

P478

Q50288154-E248E6FB-67C8-4A29-A7C9-B09010ECE0E0

P577

Q50288154-854F9757-CF74-4C5A-BE7A-66C7208849A2

P6179

Q50288154-0FE72D43-2670-44C7-8342-6A6B30C9B339

P921

Q50288154-D61B3731-D9A5-43C2-B881-137CC4430517

P932

Q50288154-CA34A00C-EA2C-4D2A-A365-BAFFB38683F5

P356

1746-1596-8-S1-S14

P1433

Diagnostic Pathology

P1476

Is HER2 amplification predictable by digital immunohistochemistry?

@en

P2093

Béla Molnár

http://www.w3.org/2001/XMLSchema#string

Daniel Szabó

http://www.w3.org/2001/XMLSchema#string

Gábor Kiszler

http://www.w3.org/2001/XMLSchema#string

László Krecsák

http://www.w3.org/2001/XMLSchema#string

Tamás Micsik

http://www.w3.org/2001/XMLSchema#string

Tibor Krenács

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer.

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.

Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens

Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation

Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer.

Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

P2888

1746-1596-8-s1-s14

P304

S14-S14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1746-1596-8-S1-S14

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023848124

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3849608

http://www.w3.org/2001/XMLSchema#string